Catalog No.
DHF14602
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
IgG Fc fragment receptor transporter alpha chain, IgG receptor FcRn large subunit p51, FcRn, FCGRT, FCRN, Neonatal Fc receptor
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P55899
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
UCB-7665, CAS: 1584645-37-3
Clone ID
Rozanolixizumab
Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial, PMID: 33219142
The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study, PMID: 29093180
Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration, PMID: 30130439
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia, PMID: 32886753
Next-generation Fc receptor-targeting biologics for autoimmune diseases, PMID: 31404703
Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies, PMID: 32833750
Autoimmune thrombocytopenia: Current treatment options in adults with a focus on novel drugs, PMID: 31449692
Current pharmacotherapeutic options for myasthenia gravis, PMID: 31670984
Erratum for the Research Article: "The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study" by P. Kiessling, R. Lledo-Garcia, S. Watanabe, G. Langdon, D. Tran, M. Bari, L. Christodoulou, E. Jones, G. Price, B. Smith, F. Brennan, I. White, S. Jolles, PMID: 29212714
Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status, PMID: 30762205
[Reaserch Advances in the Treatment of Primary Immune Thrombocytopenia--Review], PMID: 34105504
Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Predicting the Effects of Anti-FcRn Therapy on the Disposition of Endogenous IgG in Humans, PMID: 30471293
The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors, PMID: 33717213
Antiseizure Medication use in Gastric Bypass Patients and Other Post-Surgical Malabsorptive States, PMID: 33997757
For research use only. Not for human or drug use.
